Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
InMed Pharmaceuticals Inc is a biotechnology business based in the US. InMed Pharmaceuticals shares (INM) are listed on the NASDAQ and all prices are listed in US Dollars. InMed Pharmaceuticals employs 12 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $1.23 |
|---|---|
| 52-week range | $1.20 - $6.42 |
| 50-day moving average | $1.48 |
| 200-day moving average | $2.28 |
| Wall St. target price | $6.75 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.37 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.23 from 2022-01-21
| 1 week (2022-01-14) | -0.81% |
|---|---|
| 1 month (2021-12-23) | -18.00% |
| 3 months (2021-10-22) | -24.07% |
| 6 months (2021-07-23) | -50.80% |
| 1 year (2021-01-22) | -69.63% |
|---|---|
| 2 years (2020-01-19) | N/A |
| 3 years (2019-01-19) | N/A |
| 5 years (2017-01-19) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -59.55% |
| Return on equity TTM | -119.13% |
| Profit margin | 0% |
| Book value | $1.47 |
| Market capitalisation | $17.5 million |
TTM: trailing 12 months
We're not expecting InMed Pharmaceuticals to pay a dividend over the next 12 months.
You may also wish to consider:
InMed Pharmaceuticals's shares were split on a 1:33 basis on 5 July 2020. So if you had owned 33 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your InMed Pharmaceuticals shares – just the quantity. However, indirectly, the new 3200% higher share price could have impacted the market appetite for InMed Pharmaceuticals shares which in turn could have impacted InMed Pharmaceuticals's share price.
Over the last 12 months, InMed Pharmaceuticals's shares have ranged in value from as little as $1.2 up to $6.42. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while InMed Pharmaceuticals's is 1.4075. This would suggest that InMed Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
To put InMed Pharmaceuticals's beta into context you can compare it against those of similar companies.
InMed Pharmaceuticals Inc. , a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.